Rationale: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. Patient concerns: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (SBRT), showing a durable response. Interventions: After 6 months of regorafenib, a PET/CT scan revealed a focal uptake in a solid lung nodule which was treated with SBRT, whereas continuing regorafenib administration. Fourteen months later, the patient had further progression in a parasternal lymph node, but treatment with regorafenib was continued. The regorafenib-associated side effects, such us the hand-foot syndrome, were favorable managed by reducing the dose from 160 to 120 mg/day. Outcomes: Patient-reported outcome was characterized by a progression-free survival of approximately 3 years. Lessons: in presence of oligometastatic progression, a local SBRT while retaining the same systemic therapy may be a better multidisciplinary approach. Moreover, disease progression is no longer an absolute contraindication for continuing the regorafenib treatment.

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer / Roberto, Michela; Falcone, Rosa; Mazzuca, Federica; Archibugi, Livia; Castaldi, Nadia; Botticelli, Andrea; Osti, Mattia Falchetto; Marchetti, Paolo. - In: MEDICINE. - ISSN 0025-7974. - 96:48(2017). [10.1097/MD.0000000000009023]

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer

Roberto, Michela;Falcone, Rosa;Mazzuca, Federica;Archibugi, Livia;Castaldi, Nadia;Botticelli, Andrea;Osti, Mattia Falchetto;Marchetti, Paolo
2017

Abstract

Rationale: Regorafenib is the new standard third-line therapy in metastatic colorectal cancer (mCRC). However, the reported 1-year overall survival rate does not exceed 25%. Patient concerns: A 55-year-old man affected by mCRC, treated with regorafenib combined with stereotactic body radiotherapy (SBRT), showing a durable response. Interventions: After 6 months of regorafenib, a PET/CT scan revealed a focal uptake in a solid lung nodule which was treated with SBRT, whereas continuing regorafenib administration. Fourteen months later, the patient had further progression in a parasternal lymph node, but treatment with regorafenib was continued. The regorafenib-associated side effects, such us the hand-foot syndrome, were favorable managed by reducing the dose from 160 to 120 mg/day. Outcomes: Patient-reported outcome was characterized by a progression-free survival of approximately 3 years. Lessons: in presence of oligometastatic progression, a local SBRT while retaining the same systemic therapy may be a better multidisciplinary approach. Moreover, disease progression is no longer an absolute contraindication for continuing the regorafenib treatment.
2017
beyond progression; case report; colorectal cancer; oligometastatic; regorafenib; stereotactic body radiotherapy; adenocarcinoma; antineoplastic agents; colorectal neoplasms; disease progression; disease-free survival; humans; male; middle aged; neoplasm metastasis; patient reported outcome measures;phenylurea compounds; pyridines; radiosurgery; medicine
01 Pubblicazione su rivista::01a Articolo in rivista
The role of stereotactic body radiation therapy in oligometastatic colorectal cancer / Roberto, Michela; Falcone, Rosa; Mazzuca, Federica; Archibugi, Livia; Castaldi, Nadia; Botticelli, Andrea; Osti, Mattia Falchetto; Marchetti, Paolo. - In: MEDICINE. - ISSN 0025-7974. - 96:48(2017). [10.1097/MD.0000000000009023]
File allegati a questo prodotto
File Dimensione Formato  
Roberto_The-role_2017.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 209.53 kB
Formato Adobe PDF
209.53 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1122269
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 13
social impact